MX2022015509A - Diluyente de formulacion de anticuerpos. - Google Patents

Diluyente de formulacion de anticuerpos.

Info

Publication number
MX2022015509A
MX2022015509A MX2022015509A MX2022015509A MX2022015509A MX 2022015509 A MX2022015509 A MX 2022015509A MX 2022015509 A MX2022015509 A MX 2022015509A MX 2022015509 A MX2022015509 A MX 2022015509A MX 2022015509 A MX2022015509 A MX 2022015509A
Authority
MX
Mexico
Prior art keywords
diluent
antibody formulation
formulation diluent
present
drug product
Prior art date
Application number
MX2022015509A
Other languages
English (en)
Inventor
Sachin Dubey
Brice Gassiat
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of MX2022015509A publication Critical patent/MX2022015509A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un diluyente para diluir un producto farmacológico, que comprende una inmunoglobulina heterodimérica multiespecífica, para obtener un producto farmacológico listo para administrar a un paciente mediante infusión. En particular, el diluyente de la presente invención es tal que se minimiza la pérdida de material de anticuerpos.
MX2022015509A 2020-06-12 2021-06-14 Diluyente de formulacion de anticuerpos. MX2022015509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179607 2020-06-12
PCT/EP2021/065933 WO2021250275A1 (en) 2020-06-12 2021-06-14 Antibody formulation diluent

Publications (1)

Publication Number Publication Date
MX2022015509A true MX2022015509A (es) 2023-02-23

Family

ID=71094109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015509A MX2022015509A (es) 2020-06-12 2021-06-14 Diluyente de formulacion de anticuerpos.

Country Status (10)

Country Link
US (1) US20240092903A1 (es)
EP (1) EP4164594A1 (es)
JP (1) JP2023529870A (es)
KR (1) KR20230024972A (es)
CN (1) CN115996704A (es)
AU (1) AU2021288637A1 (es)
CA (1) CA3180138A1 (es)
IL (1) IL298731A (es)
MX (1) MX2022015509A (es)
WO (1) WO2021250275A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
AU2013251482B2 (en) * 2012-04-26 2018-01-04 Bioatla Llc Anti-CD22 antibodies
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
EP3618864A1 (en) 2017-05-05 2020-03-11 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US20210087267A1 (en) * 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies

Also Published As

Publication number Publication date
AU2021288637A1 (en) 2023-01-19
US20240092903A1 (en) 2024-03-21
JP2023529870A (ja) 2023-07-12
WO2021250275A1 (en) 2021-12-16
IL298731A (en) 2023-02-01
CA3180138A1 (en) 2021-12-16
KR20230024972A (ko) 2023-02-21
EP4164594A1 (en) 2023-04-19
CN115996704A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
MX2021004774A (es) Formulacion de anticuerpos.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
SG11201806348PA (en) Steroid derivative fxr agonist
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CR20220627A (es) Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
EA201790525A1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
JOP20210127A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
MX2021005085A (es) Formulacion de anticuerpo.
JOP20210034A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
MX2022015509A (es) Diluyente de formulacion de anticuerpos.
MX2023008887A (es) Combinaciones farmaceuticas que comprenden un anticuerpo anti-ly75.
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2021015573A (es) Derivados de urea como moduladores alostericos de cb1.
MX2021015298A (es) Anticuerpo anti-epha4 humano.
BR112022007102A2 (pt) Métodos para a preparação de ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.
BR112018070452A2 (pt) um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
PL435653A1 (pl) Sposób wytwarzania kwaśnej serwatki, serwatka kwaśna otrzymana tym sposobem i produkt zawierający serwatkę